Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IB1001 in GM2 Gangliosidosis
NCT03759665Phase 2Completed
- Sponsor
- IntraBio
- Start
- Jun 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of levacetylleucine in Tay-Sachs disease (TSD) and Sandhoff disease (2 arms), sponsored by IntraBio. Primary endpoint: Clinical Impression of Change in Severity at 6 weeks. Started Jun 2019; status: completed.
02
Drugs
levacetylleucine
03
Conditions
Tay-Sachs disease (TSD)Sandhoff disease
Beyond the preview
Go deeper on NCT03759665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759665.